Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138994 · ClinicalTrials.gov registry record · NA
Next Science Wound Gel Efficacy in Chronic Wound Versus Standard of Care
A NA study, sponsored by Next Science TM.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT02138994: Completed NA study, sponsored by Next Science TM.
NCT02138994 is a NA study that has completed, run by Next Science TM. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02138994, a NA study, has completed, sponsored by Next Science TM.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a 3 to 4 months, multi-site, prospective randomized clinical study of patients diagnosed with a chronic wound. The primary objective is to assess changes in healing rate, by measuring differences in wound area when treating chronic wounds with the Next Science Wound Gel compared to the Triple Antibiotic Ointment Neosporin (Standard of Care, SOC). At the end of the study period, patients may continue receiving their assigned study treatment provided they have signed the "Continuation of Treatment Informed Consent" and the rational for continuation is documented by the investigator.
Interventions
- DEVICE Next Science Wound Gel
- DRUG Triple Antibiotic Ointment Neosporin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-09 |
| Phase | NA |
What the finished NCT02138994 record still lists
NCT02138994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Next Science Wound Gel is the first listed.
NCT02138994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02138994 about?
NCT02138994 is a clinical study titled "Next Science Wound Gel Efficacy in Chronic Wound Versus Standard of Care". This is a 3 to 4 months, multi-site, prospective randomized clinical study of patients diagnosed with a chronic wound. The primary objective is to assess changes in healing rate, by measuring differences in wound area when treating chronic wounds with the Next Science Wound Gel compared to the Tripl...
What is the current status of trial NCT02138994?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2014-07. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02138994?
The interventions under investigation include: Next Science Wound Gel (DEVICE), Triple Antibiotic Ointment Neosporin (DRUG).
Who is sponsoring clinical trial NCT02138994?
This trial is sponsored by Next Science TM, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02138994's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia